NCT06063291

Single Ascending Oral Dose Phase 1 Study of ID110521156 in Healthy Adult Subjects

A Randomized, Double-blinded, Placebo-controlled, Single Ascending Dose Phase 1 Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics After a Single Oral Administration of ID110521156 in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: IlDong Pharmaceutical Co Ltd · Industry
• Sex: All
• Age: 19 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single oral doses of ID110521156 in healthy adult subjects. This is the first clinical study of ID110521156.

Conditions

• Healthy Adult Subjects

Interventions

Type	Name	Description
DRUG	ID110521156	subjects will receive a single oral dose of IMP. In the morning (all procedures must be performed at the similar clock time) on Day 1
DRUG	Placebo of ID110521156	subjects will receive a single oral dose of IMP. In the morning (all procedures must be performed at the similar clock time) on Day 1

Timeline

• Start date: 2023-11-20
• Primary completion: 2024-07-11
• Completion: 2024-07-11
• First posted: 2023-10-02
• Last updated: 2024-11-25

Locations

1 site across 1 country: South Korea